Novo Nordisk, the Denmark-based manufacturer of Ozempic, said Sept. 10 it plans to reduce approximately 9,000 of its 78,400 global roles.
The drugmaker said in a news release the workforce reductions will save 8 billion Danish Krone, or about $1 billion, by the end of 2026. Around 5,000 of the layoffs will occur in Denmark.
Novo Nordisk said the move aims to “simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.